# TroFuse-019 (NCT06312137)

> A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06312137
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non Small Cell Lung Cancer
- Interventions: Sacituzumab tirumotecan; Pembrolizumab; Cisplatin; Pemetrexed; Gemcitabine; Carboplatin; Paclitaxel; Rescue medication
- Enrollment: 780
- Primary outcome: Disease-free survival (DFS) as assessed by Blinded Independent Central Review (BICR)

## Indexed commentary on TroFuse-019 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=trofuse-019-nct06312137